Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Antioxidant Absorption

In brief

The goal of this clinical trial is to learn if Obicetrapib works to change antioxidant levels in HDL and plasma, as well as retinal tissue. The main questions it aims to answer are: Do Obicetrapib effect absorption of antioxidants in a person's blood or their eye tissue? Researchers will compare Obicetrapib to a placebo (a look-alike substance that contains no drug) to see if Obicetrapib helps improve a person's ability to absorb antioxidants. Participants will: Take Obicetrapib or a placebo every day for 4 months Visit the clinic once every 8 weeks for checkups and tests Have their blood taken and their eyes checked to measure antioxidant levels

Key facts

Study ID

NCT06982508

Run by

NewAmsterdam Pharma

People needed

100

Starts

2025-09-09

Expected to finish

2026-12-01

Last updated by the study team

2025-10-20

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Visual acuity > 20/60 in both eyes with or without corrective lenses

You may not qualify if…

• Type 2 diabetes
• Active liver disease
• Any clinically significant macular pathology

Where it is running

• Excellence Medical Research — Miami Gardens, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.